Yusuke Fukao

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy

Yoshihito Nihei, Kei Haniuda, Mizuki Higashiyama et al. · Science Advances · 2023 · 64 citations · Full text

Medicine, Nephrology, Pathology +17

Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy

Toshiki Kano, Hitoshi Suzuki, Yuko Makita et al. · Kidney International · 2021 · 46 citations

Medicine, Immunology, Nephrology +9

The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy

Mingfeng Lee, Hitoshi Suzuki, Kei Ogiwara et al. · Kidney International · 2023 · 40 citations · Full text

Life Sciences, Immunology, Pathobiology +17